EBOS Director Increases Indirect Shareholding Through On-Market Purchase

EBOS Group Limited ( (AU:EBO) ) has shared an update.

EBOS Group Limited has disclosed a change in director Stuart McLauchlan’s indirect interest in the company, following an on-market purchase of additional shares. McLauchlan, whose beneficial ownership is held via JBWere (NZ) Nominees Limited, acquired 1,500 ordinary shares on 27 February 2026 for NZ$36,054.64, increasing his holding from 3,686 to 5,186 shares.

The transaction was conducted as an on-market acquisition and did not involve any disposal of shares or changes to interests in contracts. The company confirmed that the trade did not occur during a closed period requiring prior written clearance, indicating routine portfolio adjustment rather than an exceptional governance event.

The most recent analyst rating on (AU:EBO) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited operates in the healthcare and pharmaceuticals sector, supplying medical, pharmaceutical, and related products and services across its markets. The company focuses on distribution and related support services for healthcare providers, positioning itself as a key intermediary in the medical supply chain.

Average Trading Volume: 140,545

Technical Sentiment Signal: Sell

Current Market Cap: A$4.14B

For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.